**Name: Daniel Martin Weinberger, Ph.D.**

**Term:** July 1, 2020 – June 30, 2023

**School assignment:** Yale University School of Medicine and Graduate School

**Education:** B.S. The College of William and Mary (Biology), 2005

 Ph.D. Harvard School of Public Health, 2010

**Career/Academic Appointments:**

2009 Postdoctoral fellow in Epidemiology, Harvard School of Public Health

2010-2013 Postdoctoral fellow in Epidemiology, Division of International Epidemiology and Population Studies, National Institutes of Health/Fogarty International Center

2013-2018 Assistant Professor of Epidemiology, Yale School of Public Health

2018-present Associate Professor of Epidemiology, Yale School of Public Health

2021-present Contractor (Intergovernmental Personnel Act) West Haven Veterans Administration

**Professional Honors and Recognition:**

1. International/National/Regional

2020: Article of the year for 2020 in *JAMA Internal Medicine* for “Estimation of Excess

Deaths Associated With the COVID-19 Pandemic in the United States, March to

May 2020” (first author), Article viewed 711,000 times through December 2020.

2019: Article of the year for 2019 in *American Journal of Epidemiology* for “Association

Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children” (first author)

 2018: Kenneth Rothman Prize for article of the year in *Epidemiology*. (Awarded to first

author Esra Kurum; I was senior author)

2012: Robert Austrian Research Award in Pneumococcal Vaccinology from the

International Symposium on pneumococci and pneumococcal diseases

2012: National Foundation for Infectious Diseases- Advanced Course of Vaccinology

travel grant, Annecy, France

2012: International Symposium on Pneumococci and Pneumococcal Diseases travel

grant, Brazil

2011: European Scientific Working Group on Influenza, Young Scientist Award, Malta

2008: International Symposium on Pneumococci and Pneumococcal Diseases travel

grant, Iceland

2005: College of William and Mary Alumni Association Award for Molecular Biology

2004: Barry M. Goldwater Scholarship, a competitive national scholarship program for

undergraduate students aspiring to careers in science

2004: Phi Beta Kappa, College of William and Mary

1. University

2022: Yale School of Public Health Team Science award for manuscript in PNAS

“Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa”

2021: Yale School of Public Health Investigator Research Award for manuscript in *JAMA*

*Internal Medicine* for “Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020”

2015: Pepper Older Americans Independence Center annual meeting, junior faculty

travel scholarship, Washington DC (2015)

2013: Global Health Equity Scholar

**Grant History:**

1. Current Grants

Funder: NIH/NIAID/MIDAS

ID: R01AI137093

Title: Predicting and monitoring variations in the effects of vaccines against RSV

m-P.I.: Weinberger, Pitzer, Warren

Percent Effort: 25%

Direct costs per year: $298,052

Total costs for project period: $2,278,103

Project period: 9/24/2018-8/31/2023

Funder: The Bill and Melinda Gates Foundation

ID: OPP1176267

Title: Evaluating PCV impact using data sources of variable quality from resource-poor settings

P.I.: Weinberger

Percent Effort: 10%

Direct costs per year: $181,721

Total costs for project period: $599,681

Project Period: 8/2017-6/2020 (No cost extension to 6/2022)

Funder: The Bill and Melinda Gates Foundation

ID: INV-017940

Title: Designing optimal trials for vaccines against RSV

m-P.I.: Weinberger/Pitzer/Warren

Percent Effort: 5%

Direct costs per year: $154,544

Total costs for project period: $339,998

Project Period: 10/2020-10/2022

Funder: Veteran’s Administration

(Pending)

ID: VA-BLRD

Role: co-Investigator

PI: Justice/Davies/Vashi

Percent Effort (25%)

Direct costs per year: $51,227

Total Costs for project period: $100,528

Project Period: 6/1/2021-5/31/2023

Funder: CDC/Connecticut Department of Public Health

ID: DPH Contract log #2017-0026

Title: Yale Emerging Infections Program (Non-invasive pneumococcal

pneumonia and Legionnaire’s disease sub-projects)

Role: Co-Investigator

P.I. Heimer/Niccolai

Percent Effort: 10%

Direct costs per year: $1,505,552

Project period: 1/1/2017-12/31/2021 (annual renewal)

Funder: Pfizer

Title: Evaluation of pneumococcal carriage in healthy community-dwelling adults

m-P.I.: Weinberger, Wyllie

Percent effort: 5%

Direct costs per year: $500,000

Total costs for project period: $1,400,000

Project period: 8/1/2019-7/31/2022

Funder: Merck

ID: 20-005281

Title: Spatiotemporal trends and serotype distribution of pneumococcal disease

during COVID-19

PI Weinberger/Perniciaro

Role: m-PI

Percent Effort: 5%

Direct costs per year: $107,565.46

Total costs for project period: $242,022

Project period: 2/10/2021-8/9/2022

Funder: Merck

ID: 21-004099

Title: Predicting serotype replacement resulting from capsule switch events in

Streptococcus pneumoniae

Role: m-PI

P.I. Weinberger/York

Percent Effort: 5%

Direct costs per year: $121,515

Total costs for project period: $305,307

Project period: 5/1/2021-10/31/2022

Funder: Merck

ID: AWD7774648

Title: Quantifying interactions between COVID-19 and pneumococcal disease

and the potential protective role of vaccination

Role: sub-contract PI

P.I. Bansal (Georgetown)

Percent Effort: 10%

Direct costs per year: $100,414

Total costs for project period: $130,538

Project period: 4/1/2021-3/31/2022

Funder: Centers for Disease Control and Prevention

ID: 75D30120C-09810

Title: Surface decay of SARS-CoV2 in a hospital setting

PI: Tanner

Role: Co-I

Percent effort: 5%

Direct costs per year: $247,352

Total costs for project period:  $414,315

Project period: 9/28/20-9/27/21 (NCE to 12/2021)

Funder: ZonMW (Netherlands)

Title: SPREAD study on the re-emergence of RSV in the Netherlands

PI: Bont

Role: Co-I

Percent effort: 0%

Direct costs per year: $300,000

Total costs for project period:  $300,000

Project period: 11/1/21-10/31/2022

1. Past Grants

Funder: NIH/NIAID

ID: 1R01AI123208

Title: Forecasting pneumococcal serotype frequencies to develop adult-specific

vaccines

P.I.: Weinberger

Percent Effort: 35%

Direct costs per year: $383,189

Total costs for project period: $2,537,945

Project period: 8/8/2016-7/31/2020

Agency: Pfizer

ID: WI248243 (Amendment)

Title: Evaluation of pneumococcal carriage in healthy community-dwelling adults (COVID section)

P.I.: Wyllie/Weinberger

Role on Project: Co-PI

Percent effort: 0%

Total costs for project period: $377,000

Project period: 04/15/2020-04/15/2021

Funder: National Science Foundation

ID: 2030130

Title: RAPID: Hydrologic control on SARS-CoV-2 transfer to streams

PI: Raymond

Role: m-PI

Total costs for project period: $88,155

Project period: 5/2020-4/2021

Funder: NIH/NIAID

ID: 1R56AI110449-01A1

Title: Forecasting pneumococcal serotype frequencies to develop adult-specific

vaccines

P.I.: Weinberger

Percent Effort: 26.7%

Direct costs per year: $256,163

Total costs for project period: $426,511

Project period: 7/1/2015-6/30/2016 (no cost extension to 6/30/2017)

Funder: The Bill and Melinda Gates Foundation

ID: OPP1114733

Title: Impact of pneumococcal conjugate vaccines (PCVs) among poor populations living in middle-income countries

P.I.: Weinberger

Percent Effort: 20.8%

Direct Costs per year: $675,141

Total costs for project period: $1,485,311

Project Period: 9/2014-7/2016 (no cost extension to July 2017)

Funder: Yale Climate Change and Health Initiative

Title: Consequences of climate change for the risk of enteric infections:

investigating links between hydrology and water-borne diseases

PI: Pitzer

Percent effort: 0%

Direct costs per year: $25,000

Total costs for project period: $25,000

Project period: 5/2016-4/2017

Funder: Yale Center for Clinical Investigation/NIH/NCATS

ID: UL1TR000142

Title: High-throughput methods to track the evolution of pneumococcal serotypes

P.I.: Shapiro

Percent Effort: 0%

Direct costs per year: $20,000

Total costs for project period: $40,000

Project period: 9/1/2014-9/15/2016

Funder: Yale Pepper Center/NIH/NIA

ID: P30AG021342

Title: Multifactorial determinants of pneumococcal vaccine impact in the geriatric

population

P.I.: Gill

Percent Effort: 19%

Direct costs per year: $45,000

Total costs for project period: $90,000

Project period: 7/1/2014-6/30/2016

Funder: Pfizer

ID: WI178463

Title: Factors associated with the local persistence of Prevnar-targeted serotypes

among adults

P.I.: Weinberger

Percent Effort: 19%

Direct costs per year: $48,260

Total costs for project period: $134,056

Project period: 8/1/2013-7/31/2015

Funder: Yale Climate Change and Health Initiative

Title: Effects of extreme climate events on environmental reservoirs and

dispersion of *Legionella*

PI: Weinberger

Percent effort: 0%

Direct costs per year: $25,000

Total costs for project period: $25,000

Project period: 6/2017-5/2018

Funder: Global Health Equity Scholar Program/NIH/FIC

ID: R25 TW009338

Title: Seasonal variations in bacterial disease incidence among slum and non-

slum populations

in Brazil

P.I.: Riley, Barry, Ko, Madhivanan

Percent Effort: 0%

Direct costs per year: $20,000

Total costs for project period: $20,000

Project period: 7/1/13-5/31/14

Funder: International Symposium on pneumococci and pneumococcal

diseases/Pfizer

ID: Robert Austrian Research Award

Title: Quantitative approaches for understanding the impact of conjugate

vaccines and patterns of replacement

P.I.: Weinberger

Percent Effort: 0%

Direct costs per year: $20,000

Total costs for project period: $20,000

Project period: Awarded 2012

**Invited Speaking Engagements Not Affiliated With Yale**

2022

European Society for Pediatric Infectious Diseases (ESPID), Athens, Greece. *Invited Presentation.* “Re-emergence of Invasive Pneumococcal Disease in Children in 2021/22”.

Global Expert Meeting on Respiratory Viruses (GEM), Torino, Italy (delivered virtually). *Invited Presentation.*

International Symposium for Pneumococci and Pneumococcal Diseases, Toronto, Canada

2021

 Veteran’s Administration, Delayed Care Program, Expertise Presentation.

“Attributable Mortality”. Webinar.

WHO RSV surveillance meeting. *Invited presentation. “*RSV

seasonality – learnings from 2020”. Virtual meeting.

*ReSViNET (*GlobalRSV virus network.) *Webinar*. “RSV transmission dynamics

and the effects of social distancing.” (>200 live participants)

University Medical Centre Utrecht/Utrecht University Infectious disease modeling

seminar. Utrecht, the Netherlands *Seminar.*

Matrivax Lunch and Learn seminar. *Invited presentation.* “Historical perspectives on pneumococcal vaccines and prospects for the future”

ReSViNET annual meeting (Virtual). *Invited presentation.* “RSV dynamics during COVID times.”

2020

 WHO Modeling Working group on COVID-19 *Invited*

*presentation.* “Estimating the early toll of COVID-19 in the United States”

Bocconi University, Milan Italy. *Invited seminar*. “Estimating the early

toll of COVID-19 in the United States”

University Medical Centre Utrecht/Wilhelmina Children’s Hospital, Utrecht, The

Netherlands. *Invited seminar*. “Bacterial-viral co-infections”,

St. Charles Health System, Oregon. *Grand Rounds.* “Excess deaths associated

with COVID-19 in the United States.”

Harvard School of Public Health, Infectious Disease Epidemiology seminar

series. *Invited seminar.* (Canceled due to COVID-19)

2019

5th ESCMID Conference on Vaccines. Bilbao, Spain. *Invited presentation*. “Appropriate endpoints in RTI vaccine trials: Impact vs efficacy.”

ASM General Meeting 2019 (ASM Microbe). San Francisco, CA. *Invited presentation.* “Evidence that carriage in 3- 5 year olds is key to herd protection from vaccine-type pneumococcal disease”

2018

PAHO/WHO/Gates/CDC meeting on the effect of PCVs on mortality. Washington, DC. “Results from a 10-country analysis in Latin America”

International Symposium on Pneumococci and Pneumococcal Diseases. Melbourne, Australia. *“Meet the experts” panel.* “Use of administrative data to evaluate the impact of vaccines”

2017

PAHO/Gates meeting on evaluation of pneumococcal vaccine impact. Washington, DC. *Invited presentation.* “New approaches for estimating the effects of PCVs”

Institute for Disease Modeling; annual symposium. Seattle, WA. *Invited presentation.* “New approaches for estimating the effects of PCVs”

Harvard School of Public Health; Department of Immunology and Infectious

Diseases. Boston, MA. *Invited seminar.* “Implications of pathogen interactions for pneumococcal conjugate vaccines”

2016

 Dutch Institute for Public Health and the Environment (RIVM). Bilthoven, The

Netherlands. *Invited presentation at the workshop on multi-strain pathogen dynamics.* ‘Biological determinants of pneumococcal competition and serotype replacement’

 International Symposium on Pneumococci and Pneumococcal Diseases.

 Glasgow, Scotland, *“Meet the experts” session on use of mathematical modeling*

 *to understand pneumococcal biology.*

Statens Serum Institut, Copenhagen, Denmark. *Invited presentation at the Fritz Kaufmann Memorial Award Symposium.* ‘Developing a more sensible strategy for protecting adults against pneumococcal disease’

Pan American Health Organization, Washington, DC. Meeting on vaccine impact evaluation. *Invited presentation*. “Developing novel methods to improve reliability of PCV impact studies

World Health Organization technical expert consultation on “Reduced Dose Schedules for Pneumococcal Conjugate Vaccines,” Geneva, Switzerland. *Invited presentation.* Using administrative data to evaluate PCV impacts

against pneumonia: challenges and solutions

 2015

*ICAAC (*Interscience Conference of Antimicrobial Agents and Chemotherapy), San Diego, CA, *Invited symposium speaker.* “Evaluating PCV impact against pneumonia: how to avoid being tricked by your data”

 Naval Medical Research Center, Silver Spring, MD. *Invited seminar*. “Ongoing

challenges in estimating and predicting the impacts of pneumococcal vaccination”

 Palestinian/Israeli Collaborative Research Annual Meeting, Jerusalem*. Invited*

 *presentation.* ‘S. pneumoniae: A commensal? Or an invasive pathogen?’

 2014

Federal University of Brazil (Bahia), Pharmacy School. Salvador, Brazil. *Invited seminar.* ‘Pneumococcal serotype replacement: can strain biology help predict the future?’

Harvard School of Public Health, Department of Epidemiology, Center for Communicable Disease Dynamics, Boston, MA,. *Invited Seminar.* ‘Understanding the burden of pneumococcal disease through studies of viral co-infections’

College of William and Mary Department of Biology. Williamsburg, VA. *Invited seminar.* ‘Pneumococcal serotype replacement: can strain biology help predict the future?

International Symposium on Pneumococci and Pneumococcal Diseases. Hyderabad, India. *Invited oral presentation.* ‘Using pneumococcal carriage data to predict and monitor post-vaccination changes in disease’

2013

World Health Organization. “Short and long-term impact evaluation framework” for pneumococcal vaccine. Geneva, Switzerland. *Invited presentation.* ‘Using pneumococcal carriage data to predict and monitor post-vaccination changes in disease’

Infectious Disease Society of America (IDSA) annual meeting (IDWeek), San Francisco. *Invited oral presentation.* ‘Serotype Persistence and Replacement after Vaccines: Can We Predict the Future?

European Respiratory Society meeting, Barcelona, Spain. *Invited oral presentation.* ‘The pneumococcus and its capsule’

Fundação Oswaldo Cruz, Salvador, Brazil. *Invited seminar.* ‘Pneumococcal

serotype replacement: can strain biology help predict the future?’

2012

Emory University, Rollins School of Public Health, Department of Global Health, Atlanta. *Seminar presentation*. Pneumococcal disease patterns:
ecology, capsule, and co-infections

University of Georgia, College of Public Health, Athens, GA. *Invited seminar.*

Pneumococcal disease patterns: ecology, capsule, and co-infections

4th Helsinki Symposium on HPV Vaccination, Helsinki. *Invited presentation*. ‘Strain replacement following vaccination: the example of pneumococcus’

2011

Johns Hopkins School of Public Health, International Vaccine Access Center,

Baltimore, MD. *Invited seminar*. ‘Studies of influenza and pneumococcal disease’

Johns Hopkins School of Public Health, Center for American Indian Health

Baltimore, MD. *Invited seminar*. Use of pneumococcal carriage data to predict disease incidence post-PCV: a proposed method

Center for Disease Dynamics, Economics, and Policy, Washington, DC. *Invited seminar.* ‘Pneumococcal serotype ecology: implications for vaccine effectiveness’

Agency for Healthcare Research and Quality, Washington, DC. Annual partners meeting. *Oral presentation.* ‘Pandemic influenza and pneumococcal disease’

2010

UMC Utrecht Infection and Immunity Center, Utrecht, The Netherlands. *Invited seminar.* ‘Pneumococcal serotype replacement: biology, ecology, and future prospects

Historical Influenza Pandemics: Lessons Learned; Copenhagen, Denmark*. Invited oral presentation.* ‘Epidemiologic patterns of pneumococcal serotypes:
 potential implications for influenza’

**Peer-Reviewed Presentations Given at Meetings not affiliated with Yale**

2018

International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); Melbourne, Australia. 6 accepted abstracts from my group (5 posters, 1 oral):

‘Identifying age groups associated with indirect protection of PCVs

‘Improving credibility of PCV impact estimates using pooled analysis’

‘Effect of sample size on the ability to estimate the impact of pneumococcal conjugate vaccines using time series data’

‘Identifying non-random patterns of capsule switching in pneumococcus’

‘Effect of environmental conditions on the growth of pneumococcal serotypes’

‘Over-representation of pneumococcal serotypes in disease in adults’

2017

9th International Conference on *Legionella*, Rome. *Poster presentation* (MPH student Kelsie Cassell). “Association between sporadic legionellosis and river systems in Connecticut”

American Society for Microbiology General Meeting 2017, New Orleans. *Poster*

*presentation.* ‘Effect of environmental conditions on the growth and competitiveness of pneumococcal serotypes’

2016

International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); Glasgow, Scotland; *Oral presentation* (presented by postdoc Christian Bruhn); *three* *poster presentations:*

‘Pitfalls and potentials of using comparison outcomes in studies evaluating the impact of vaccines’

‘Bayesian model averaging with change points: a flexible method to assess the impact of pneumococcal vaccines’

‘Challenges in using hospitalization data to estimate PCV impact’

‘Mortality Benefits of PCV10 In the Context of an Epidemiologic Transition: The Case of Brazil’

2014

Infectious Disease Society of America General Meeting, Philadelphia, *Poster presentation.* ‘Predicting the indirect impacts of pneumococcal conjugate vaccine use among children on disease rates in adults’

2012

International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Brazil. *Oral presentation and poster presentation.* ‘Quantitative Approaches for Understanding the Impact of Conjugate Vaccines:

Results of the ISPPD-8 Robert Austrian Research Award’

2011

European Scientific Working Group on Influenza (ESWI) conference, Malta. *Oral*

*presentation. ‘*Evaluating the effect of respiratory syncytial virus (RSV) and influenza activity on estimates of pneumococcal vaccine impact’

2010

International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); Tel Aviv, Israel. *Oral presentation and 2 poster presentations:*

*‘Evaluating the effect of respiratory syncytial virus (RSV) and influenza activity on estimates of pneumococcal vaccine impact’*

‘The effect of influenza on invasive pneumococcal disease varies with age and serotype’

2008

International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); Reykjavik, Iceland. *Poster presentation.* ‘Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage.’

 2005

American Society for Microbiology General Meeting; Atlanta, Georgia. *Poster presentation.* ‘Expression of the Helicobacter pylori adhesin SabA is controlled via phase variation and the ArsRS signal transduction system.’

**Professional Service**

**Grant peer review**

2022: NIH study section: *Ad hoc* reviewer for the CRFS study section, June 2022

2021: NIH study section*. Ad hoc* study section for “Emergency Awards for COVID-

19/SARS-CoV-2” (ZAI1-IS-W-M1), January 2021.

2020: NIH study section. *Ad hoc* reviewer for the CRFS study section, June 2020

2015-2020: Wellcome Trust. *Ad hoc* reviewer

2015-2016: Medical Research Council (MRC)

2015: Thrasher Foundation

2011: Meningitis UK

**Journal service**

2022: Guest Editor at *PNAS*

2020-present:AssociateEditor at *Pneumonia*

2020-present:AssociateEditor at *FEMS Microbe*

2014-21: Guest Editor for *PLOS Computational Biology*

2021: Guest Editor for supplement to *Clinical Infectious Diseases* on RSV mortality

2019-20: Associate Editor for *PLOS Neglected Tropical Diseases*

2008-present: Peer review journal articles for *New England Journal of Medicine, PNAS,*

*The* *Lancet*, *Lancet Infectious Diseases*, JAMA, JAMA *Internal Medicine*, *PLoS Medicine*, *PLoS Pathogens*, *Journal of Bacteriology, Emerging Infectious Diseases*, *PLoS One*, *Vaccine*, *Clinical Microbiology and Infection*, *Scandinavian Journal of Infectious Diseases*, *Journal of Medical Microbiology*, *Environmental Health Perspectives*.

 **Working groups and advisory groups**

2018-2021

World Health Organization (WHO) Working Group to develop a technical guide on the use of administrative data to monitor the impact of pneumococcal vaccines. Includes representatives from WHO, CDC, and PAHO.

 2020

Scientific Advisory Group: Duke-Margolis COVID-19 Symptom Data Challenge. Provide guidance on the development of a data competition to create useful public health tools from the Facebook COVID-19 symptom survey tool.

**Workshops and conference organized**

2023

Co-chair of the organizing committee for the biennial RESVINET conference, the largest international conference dedicated to the epidemiology and clinical treatment of RSV, Lisbon, Portugal.

 2022

Virtual training workshop on vaccine evaluation methods, with attendees from 13 countries (free registration thanks to support from the Bill and Melinda Gates Foundation), organizer and instructor.

2019

PAHO workshop on using mortality data to evaluate vaccine impact. 2.5 day training workshop held at Yale with 20 representatives of 10 ministries of health around Latin America, as well representatives from CDC and WHO. Lead organizer, instructor, and host.

2010-2013

 NIH-Fogarty training workshops in the use of time series analysis to evaluate the

 burden of influenza. Workshops in Lima, Kathmandu, Copenhagen, Beijing

 **Technical consultations for government/non-profit**

2021

 Gates Foundation: RSV during COVID times, ad hoc consultations

2020

 White House Council of Economic Advisors: Technical consultation to discuss

estimates of excess deaths related to COVID-19

 Rep Ted Deutch (D-FL). Technical consultation to discuss excess death

estimates during COVID-19 in Florida

2018

CDC: Technical consultation for studies evaluating effectiveness of use of Prevnar in adults. The results of these analyses are informing the CDC’s Advisory Committee on Immunization Practices decision regarding the continued use of PCV13 in adults.

2018

World Health Organization: Technical consultation for the Data Safety Monitoring Board for the RTS,S malaria vaccine

2018

Pan American Health Organization: Consultation on the use of administrative data for evaluating the impact of pneumococcal vaccines against mortality

2017

World Health Organization: Expert technical consultation for the pneumococcal working group of SAGE: Optimization of Pneumococcal Conjugate Vaccine Use. Geneva, Switzerland

2016-present

Technical training and consulting for CDC and the Pan American Health Organization (PAHO) on using synthetic controls to evaluate the impacts of vaccines. New Haven, CT.

Pan American Health Organization/WHO: Technical consultation on vaccine impact studies. Washington, DC

World Health Organization: Technical expert consultation on reduced dose schedules for pneumococcal conjugate vaccines. Geneva, Switzerland.

2015

GAVI: The Vaccine Alliance: Meeting on uncertainty analysis for vaccine impact evaluations, Montreux, Switzerland

2013

World Health Organization: Meeting on the Short and Long Term Impact of Pneumococcal Conjugate Vaccines, Geneva

2012

Australian, UK, and Nordic working group on type-replacement following HPV vaccination. Helsinki, Finland

**Technical consultations for industry**

 2021

 Technical consultations with Pfizer, Moderna, Janssen, Sanofi Pasteur on RSV

 dynamics and implications for clinical trials

 2021-22

 Merck (Manufacturer of PCV15): Vaccine advisory board member

 2020

 Pfizer (Manufacturer of PCV20): Advisory board

 Merck (Manufacturer of PPV23, PCV10): Technical advisory group

 Janssen Pharmaceuticals (Johnson and Johnson): manufacturer of RSV

 vaccine for adults.

 2019

 Morgan Stanley: Consultation on climate change and health

 2015-2019

 Pfizer (manufacturer of PCV7/13): Vaccine advisory boards 2015-2019

 2014-2019

 Merck (manufacturer of PCV15): *ad hoc* vaccine advisory boards

2015-2017

Affinivax (developer of novel pneumococcal vaccine): Consultant

 2016

 GlaxoSmithKline (Manufacturer of PCV10): *Ad hoc* consultant

 2016-present

 Fluid-Screen (developer of novel pathogen diagnostics): *Ad-hoc* consultant

**International scientific conference committees**

2022 (Toronto)

International symposium on pneumococci and pneumococcal disease

(ISPPD), Melbourne, Australia, International Scientific Committee. Review and rank submissions for this major international conference (~1200 attendees); organize pre-conference workshop

2017/18 (Melbourne)

International symposium on pneumococci and pneumococcal disease

(ISPPD), Melbourne, Australia, International Scientific Organizing Committee. Plan and chair conference session on Epidemiology and Mathematical Modeling for this major international conference (~1200 attendees)

2015/16 (Glasgow)

International symposium on pneumococci and pneumococcal disease

(ISPPD), Glasgow, Scotland. International Scientific Organizing Committee. Plan and chair conference session on Ecology and Evolution for this major international conference (~1200 attendees)

 **External doctoral examinations**

 2022

 International examiner, Aga Khan University, Pakistan

2019

International opponent, University of Iceland

**Yale University Service**

School of Public Health Committees

2022-23 Yale School of Public Health IT Advisory Committee (co-chair)

2021-22: Yale School of Public Health/EMD PhD admissions committee

2021-22: Yale School of Public Health, Committee for Academic and

Professional Integrity (CAPI)

2019-present: Yale Climate Change and Health Initiative executive committee

2018-present: Public Health Modeling concentration executive committee

2015-17: EMD departmental seminar committee

2013-15: Yale Public Health Modeling seminar series

 University-wide committees

2022-23 Yale University Provost’s IT Services Advisory Committee

Other University Service

2019/2020, 2021-present

* Director of the degree program for the Master of Science with a Concentration in Epidemiology of Infectious Diseases, quantitative specialization

2022

* Internal grant pre-review for NIH proposals

2013-present

* Serve as academic advisor for YSPH and Yale College students
* Advisor for 1 undergraduate thesis in 2017/18
* Doctoral qualifying exam committees at YSM and YSPH
* Reader for MPH and PhD theses and dissertations:

**PUBLICATIONS/MANUSCRIPTS/SOFTWARE**

*Peer Reviewed Original Research*

1. Goodwin AC, **Weinberger DM**, Ford CB, Nelson JC, Snider JD, Hall JD, Paules CI, Peek RM, Forsyth MH. Expression of the Helicobacter pylori adhesin SabA is controlled via phase variation and the ArsRS signal transduction system. *Microbiology* (Reading). 2008;154(Pt 8):2231-40. Epub 2008/08/01. doi: 10.1099/mic.0.2007/016055-0.
2. **Weinberger DM**, Dagan R, Givon-Lavi N, Regev-Yochay G, Malley R, Lipsitch M. Epidemiologic evidence for serotype-specific acquired immunity to pneumococcal carriage. *Journal of Infectious Diseases*. 2008;197(11):1511-8. Epub 2008/05/13. doi: 10.1086/587941.
3. **Weinberger DM**, Trzciński K, Lu YJ, Bogaert D, Brandes A, Galagan J, Anderson PW, Malley R, Lipsitch M. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. *PLoS Pathogens*. 2009;5(6):e1000476. Epub 2009/06/13. doi: 10.1371/journal.ppat.1000476.
4. D Bogaert, **Weinberger DM**, Thompson, C, Lipsitch M, Malley R. Impaired innate and adaptive immunity to *Streptococcus pneumoniae* and its effect on colonization in an infant mouse model. *Infection and Immunity*. 2009 Apr;77(4):1613-22. Epub 2009 Jan 21. doi: 10.1128/IAI.00871-08.
5. **Weinberger DM**, Harboe ZB, Sanders EA, Ndiritu M, Klugman KP, Rückinger S, Dagan R, Adegbola R, Cutts F, Johnson HL, O'Brien KL, Scott JA, Lipsitch M. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. *Clinical Infectious Diseases*. 2010;51(6):692-9. Epub 2010/08/19. doi: 10.1086/655828.
6. **Weinberger DM**, Harboe ZB, Flasche S, Scott JA, Lipsitch M. Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. *Epidemiology*. 2011;22(2):199-207. Epub 2011/06/08. doi: 10.1097/EDE.0b013e3182087634.
7. Lipsitch M, Abdullahi O, DʼAmour A, Xie W, **Weinberger DM**, Tchetgen Tchetgen E, Scott JA. Estimating rates of carriage acquisition and clearance and competitive ability for pneumococcal serotypes in Kenya with a Markov transition model. *Epidemiology*. 2012;23(4):510-9. Epub 2012/03/24. doi: 10.1097/EDE.0b013e31824f2f32.
8. Moffitt KL, Yadav P, **Weinberger DM**, Anderson PW, Malley R. Broad antibody and T cell reactivity induced by a pneumococcal whole-cell vaccine. *Vaccine*. 2012;30(29):4316-22. Epub 2012/06/12. doi: 10.1016/j.vaccine.2012.01.034.
9. **Weinberger DM**, Krause TG, Mølbak K, Cliff A, Briem H, Viboud C, Gottfredsson M. Influenza epidemics in Iceland over 9 decades: changes in timing and synchrony with the United States and Europe. *American Journal of Epidemiology*. 2012;176(7):649-55. Epub 2012/09/11. doi: 10.1093/aje/kws140.
10. **Weinberger DM**, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. *Journal of Infectious Diseases*. 2012;205(3):458-65. Epub 2011/12/14. doi: 10.1093/infdis/jir749.
11. Hyams C, Trzcinski K, Camberlein E, **Weinberger DM**, Chimalapati S, Noursadeghi M, Lipsitch M, Brown JS. Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonization with C3b/iC3b. *Infection and Immunity*. 2013;81(1):354-63. Epub 2012/11/14. doi: 10.1128/iai.00862-12.
12. Li Y, **Weinberger DM**, Thompson CM, Trzciński K, Lipsitch M. Surface charge of Streptococcus pneumoniae predicts serotype distribution. *Infection and Immunity*. 2013;81(12):4519-24. Epub 2013/10/02. doi: 10.1128/iai.00724-13.
13. Shrestha S, Foxman B, **Weinberger DM**, Steiner C, Viboud C, Rohani P. Identifying the interaction between influenza and pneumococcal pneumonia using incidence data. *Science Translational Medicine*. 2013;5(191):191ra84. Epub 2013/06/28. doi: 10.1126/scitranslmed.3005982.
14. **Weinberger DM**, Bruden DT, Grant LR, Lipsitch M, O'Brien KL, Pelton SI, Sanders EA, Feikin DR. Using pneumococcal carriage data to monitor postvaccination changes in invasive disease. *American Journal of Epidemiology*. 2013;178(9):1488-95. Epub 2013/09/10. doi: 10.1093/aje/kwt156.
15. **Weinberger DM**, Givon-Lavi N, Shemer-Avni Y, Bar-Ziv J, Alonso WJ, Greenberg D, Dagan R. Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. *Emerging Infectious Diseases.*2013;19(7):1084-91. Epub 2013/06/15. doi: 10.3201/eid1907.121625.
16. **Weinberger DM**, Harboe ZB, Viboud C, Krause TG, Miller M, Mølbak K, Konradsen HB. Serotype-specific effect of influenza on adult invasive pneumococcal pneumonia. *Journal of Infectious Diseases*. 2013;208(8):1274-80. Epub 2013/08/01. doi: 10.1093/infdis/jit375.
17. Harboe ZB, Dalby T, **Weinberger DM**, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. *Clinical Infectious Diseases*. 2014;59(8):1066-73. Epub 2014/07/19. doi: 10.1093/cid/ciu524.
18. Lewnard JA, Jirmanus L, Júnior NN, Machado PR, Glesby MJ, Ko AI, Carvalho EM, Schriefer A, **Weinberger DM**. Forecasting temporal dynamics of cutaneous leishmaniasis in Northeast Brazil. *PLoS Neglected Tropical Diseases*. 2014;8(10):e3283. Epub 2014/10/31. doi: 10.1371/journal.pntd.0003283.
19. Olafsdottir LB, Erlendsdóttir H, Melo-Cristino J, **Weinberger DM**, Ramirez M, Kristinsson KG, Gottfredsson M. Invasive infections due to Streptococcus pyogenes: seasonal variation of severity and clinical characteristics, Iceland, 1975 to 2012. *Euro Surveillance*. 2014;19(17):5-14. Epub 2014/05/14.
20. Tan Y, Lam TT, Wu C, Lee SS, Viboud C, Zhang R, **Weinberger DM**. Increasing similarity in the dynamics of influenza in two adjacent subtropical Chinese cities following the relaxation of border restrictions. *Journal of General Virology*. 2014;95(Pt 3):531-8. Epub 2013/12/07. doi: 10.1099/vir.0.059998-0.
21. **Weinberger DM**, Grant LR, Steiner CA, Weatherholtz R, Santosham M, Viboud C, O'Brien KL. Seasonal drivers of pneumococcal disease incidence: impact of bacterial carriage and viral activity. *Clinical Infectious Diseases*. 2014;58(2):188-94. Epub 2013/11/06. doi: 10.1093/cid/cit721.
22. **Weinberger DM**, Harboe ZB, Viboud C, Krause TG, Miller M, Mølbak K, Konradsen HB. Pneumococcal disease seasonality: incidence, severity and the role of influenza activity. *European Respiratory Journal*. 2014;43(3):833-41. Epub 2013/09/17. doi: 10.1183/09031936.00056813.
23. Humes EA, **Weinberger DM**, Kudish KS, Hadler JL. Trends in hospitalizations with primary varicella and herpes zoster during the prevaricella and initial postvaricella and herpes zoster vaccine eras, connecticut, 1994-2012. *Open Forum Infectious Diseases*. 2015;2(1):ofv001. Epub 2015/06/03. doi: 10.1093/ofid/ofv001.
24. Trzciński K, Li Y, **Weinberger DM**, Thompson CM, Cordy D, Bessolo A, Malley R, Lipsitch M. Effect of Serotype on Pneumococcal Competition in a Mouse Colonization Model. *mBio*. 2015;6(5):e00902-15. Epub 2015/09/17. doi: 10.1128/mBio.00902-15.
25. **Weinberger DM**, Klugman KP, Steiner CA, Simonsen L, Viboud C. Association between respiratory syncytial virus activity and pneumococcal disease in infants: a time series analysis of US hospitalization data. *PLoS Medicine*. 2015;12(1):e1001776. Epub 2015/01/07. doi: 10.1371/journal.pmed.1001776.
26. **Weinberger DM**, Warren JL, Steiner CA, Charu V, Viboud C, Pitzer VE. Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus. *Clinical Infectious Diseases*. 2015;61(4):506-14. Epub 2015/04/24. doi: 10.1093/cid/civ331.
27. Lewnard JA, Givon-Lavi N, Huppert A, Pettigrew MM, Regev-Yochay G, Dagan R, **Weinberger DM**. Epidemiological Markers for Interactions Among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Upper Respiratory Tract Carriage. *Journal of Infectious Diseases*. 2016;213(10):1596-605. Epub 2015/12/26. doi: 10.1093/infdis/jiv761.
28. Lewnard JA, Huppert A, Givon-Lavi N, Pettigrew MM, Regev-Yochay G, Dagan R, **Weinberger DM**. Density, Serotype Diversity, and Fitness of Streptococcus pneumoniae in Upper Respiratory Tract Cocolonization With Nontypeable Haemophilus influenzae. *Journal of Infectious Diseases*. 2016;214(9):1411-20. Epub 2016/08/20. doi: 10.1093/infdis/jiw381.
29. Menezes AP, Azevedo J, Leite MC, Campos LC, Cunha M, Carvalho Mda G, Reis MG, Ko AI, **Weinberger DM**, Ribeiro G, Reis JN. Nasopharyngeal carriage of Streptococcus pneumoniae among children in an urban setting in Brazil prior to PCV10 introduction. *Vaccine*. 2016;34(6):791-7. Epub 2016/01/09. doi: 10.1016/j.vaccine.2015.12.042.
30. Noveroske DB, Warren JL, Pitzer VE, **Weinberger DM**. Local variations in the timing of RSV epidemics. *BMC Infectious Diseases*. 2016;16(1):674. Epub 2016/11/12. doi: 10.1186/s12879-016-2004-2.
31. Oliveira CR, Costa GSR, Paploski IAD, Kikuti M, Kasper AM, Silva MMO, Tavares AS, Cruz JS, Queiroz TL, Lima H, Calcagno J, Reis MG, **Weinberger DM**, Shapiro ED, Ko AI, Ribeiro GS. Influenza-like illness in an urban community of Salvador, Brazil: incidence, seasonality and risk factors. *BMC Infectious Diseases*. 2016;16:125. Epub 2016/03/16. doi: 10.1186/s12879-016-1456-8.
32. Pingali SC, Warren JL, Mead AM, Sharova N, Petit S, **Weinberger DM**. Association Between Local Pediatric Vaccination Rates and Patterns of Pneumococcal Disease in Adults. *Journal of Infectious Diseases*. 2016;213(4):509-15. Epub 2015/08/28. doi: 10.1093/infdis/jiv431.
33. **Weinberger DM**, Grant LR, Weatherholtz RC, Warren JL, O'Brien KL, Hammitt LL. Relating Pneumococcal Carriage Among Children to Disease Rates Among Adults Before and After the Introduction of Conjugate Vaccines. *American Journal of Epidemiology*. 2016;183(11):1055-62. Epub 2016/05/18. doi: 10.1093/aje/kwv283.
34. Antillón M, Warren JL, Crawford FW, **Weinberger DM**, Kürüm E, Pak GD, Marks F, Pitzer VE. The burden of typhoid fever in low- and middle-income countries: A meta-regression approach. *PLoS Neglected Tropical Diseases*. 2017;11(2):e0005376. Epub 2017/02/28. doi: 10.1371/journal.pntd.0005376.
35. Bruhn CA, Hetterich S, Schuck-Paim C, Kürüm E, Taylor RJ, Lustig R, Shapiro ED, Warren JL, Simonsen L, **Weinberger DM**. Estimating the population-level impact of vaccines using synthetic controls. *PNAS*. 2017;114(7):1524-9. Epub 2017/02/06. doi: 10.1073/pnas.1612833114.
36. Colombe S, Togami E, Gelaw F, Antillon M, Fuentes R, **Weinberger DM**. Trends and correlates of cystic echinococcosis in Chile: 2001-2012. *PLoS Neglected Tropical Diseases*. 2017;11(9):e0005911. Epub 2017/09/16. doi: 10.1371/journal.pntd.0005911.
37. Kürüm E, Warren JL, Schuck-Paim C, Lustig R, Lewnard JA, Fuentes R, Bruhn CAW, Taylor RJ, Simonsen L, **Weinberger DM**. Bayesian Model Averaging with Change Points to Assess the Impact of Vaccination and Public Health Interventions. *Epidemiology*. 2017;28(6):889-97. Epub 2017/08/03. doi: 10.1097/ede.0000000000000719.
38. Lewnard JA, Givon-Lavi N, **Weinberger DM**, Lipsitch M, Dagan R. Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media After Rollout of Pneumococcal Conjugate Vaccines. *Clinical Infectious Diseases*. 2017;65(11):1853-61. Epub 2017/10/12. doi: 10.1093/cid/cix673.
39. Niccolai LM, Meek JI, Brackney M, Hadler JL, Sosa LE, **Weinberger DM**. Declines in Human Papillomavirus (HPV)-Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008-2015. *Clinical Infectious Diseases*. 2017;65(6):884-9. Epub 2017/05/19. doi: 10.1093/cid/cix455.
40. Robbiani DF, Bozzacco L, Keeffe JR, Khouri R, Olsen PC, Gazumyan A, Schaefer-Babajew D, Avila-Rios S, Nogueira L, Patel R, Azzopardi SA, Uhl LFK, Saeed M, Sevilla-Reyes EE, Agudelo M, Yao KH, Golijanin J, Gristick HB, Lee YE, Hurley A, Caskey M, Pai J, Oliveira T, Wunder EA, Jr., Sacramento G, Nery N, Jr., Orge C, Costa F, Reis MG, Thomas NM, Eisenreich T, **Weinberger DM**, de Almeida ARP, West AP, Jr., Rice CM, Bjorkman PJ, Reyes-Teran G, Ko AI, MacDonald MR, Nussenzweig MC. Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. *Cell*. 2017;169(4):597-609 e11. Epub 2017/05/06. doi: 10.1016/j.cell.2017.04.024.
41. Schuck-Paim C, Taylor RJ, Simonsen L, Lustig R, Kürüm E, Bruhn CA, **Weinberger DM**. Challenges to estimating vaccine impact using hospitalization data. *Vaccine*. 2017;35(1):118-24. Epub 2016/12/03. doi: 10.1016/j.vaccine.2016.11.030.
42. Warren JL, Pingali SC, **Weinberger DM**. Spatial Variability in the Persistence of Pneumococcal Conjugate Vaccine-targeted Pneumococcal Serotypes Among Adults. *Epidemiology*. 2017;28(1):119-26. Epub 2016/08/20. doi: 10.1097/ede.0000000000000551.
43. Warren JL, Shioda K, Kürüm E, Schuck-Paim C, Lustig R, Taylor RJ, Simonsen L, **Weinberger DM**. Impact of Pneumococcal Conjugate Vaccines on Pneumonia Hospitalizations in High- and Low-Income Subpopulations in Brazil. *Clinical Infectious Diseases*. 2017;65(11):1813-8. Epub 2017/10/12. doi: 10.1093/cid/cix638.
44. Cassell K, Gacek P, Warren JL, Raymond PA, Cartter M, **Weinberger DM**. Reply to Rucinski et al. *Journal of Infectious Diseases*. 2018;218(4):670-1. Epub 2018/04/17. doi: 10.1093/infdis/jiy202.
45. Cassell K, Gacek P, Warren JL, Raymond PA, Cartter M, **Weinberger DM**. Association Between Sporadic Legionellosis and River Systems in Connecticut. *Journal of Infectious Diseases*. 2018;217(2):179-87. Epub 2017/12/07. doi: 10.1093/infdis/jix531.
46. Briskin EA, Casanovas-Massana A, Ryff KR, Morales-Estrada S, Hamond C, Perez-Rodriguez NM, Benavidez KM, **Weinberger DM**, Castro-Arellano I, Wunder EA, Sharp TM, Rivera-Garcia B, Ko AI. Seroprevalence, Risk Factors, and Rodent Reservoirs of Leptospirosis in an Urban Community of Puerto Rico, 2015. *Journal of Infectious Diseases*. 2019;220(9):1489-97. Epub 2019/07/26. doi: 10.1093/infdis/jiz339.
47. Cassell K, Gacek P, Rabatsky-Ehr T, Petit S, Cartter M, **Weinberger DM**. Estimating the True Burden of Legionnaires' Disease. *American Journal of Epidemiology*. 2019;188(9):1686-94. Epub 2019/06/22. doi: 10.1093/aje/kwz142.
48. Schuck-Paim C, Taylor RJ, Alonso WJ, **Weinberger DM**, Simonsen L. Effect of pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in Brazil: a retrospective observational study. *Lancet Global Health*. 2019;7(2):e249-e56. Epub 2019/01/27. doi: 10.1016/s2214-109x(18)30455-8.
49. Shioda K, Schuck-Paim C, Taylor RJ, Lustig R, Simonsen L, Warren JL, **Weinberger DM**. Challenges in Estimating the Impact of Vaccination with Sparse Data. *Epidemiology*. 2019;30(1):61-8. Epub 2018/10/20. doi: 10.1097/ede.0000000000000938.
50. Tóthpál A, Desobry K, Joshi SS, Wyllie AL, **Weinberger DM**. Variation of growth characteristics of pneumococcus with environmental conditions. *BMC Microbiology*. 2019;19(1):304. Epub 2019/12/28. doi: 10.1186/s12866-019-1671-8.
51. **Weinberger DM**, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-Derived Protection Against Colonization in Toddlers and Preschool-Aged Children. *American Journal of Epidemiology*. 2019;188(1):160-8. Epub 2018/11/22. doi: 10.1093/aje/kwy219.
52. **Weinberger DM**, Warren JL, Dalby T, Shapiro ED, Valentiner-Branth P, Slotved HC, Harboe ZB. Differences in the Impact of Pneumococcal Serotype Replacement in Individuals With and Without Underlying Medical Conditions. *Clinical Infectious Diseases*. 2019;69(1):100-6. Epub 2018/10/16. doi: 10.1093/cid/ciy875.
53. Jimbo Sotomayor R, Toscano CM, Sánchez Choez X, Vilema Ortíz M, Rivas Condo J, Ghisays G, Haneuse S, **Weinberger DM**, McGee G, de Oliveira LH. Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: Time series analyses. *Vaccine*. 2020;38(45):7033-9. Epub 2020/09/29. doi: 10.1016/j.vaccine.2020.09.032.
54. Joshi SS, Al-Mamun MA, **Weinberger DM**. Correlates of Nonrandom Patterns of Serotype Switching in Pneumococcus. *Journal of Infectious Diseases*. 2020;221(10):1669-76. Epub 2019/12/26. doi: 10.1093/infdis/jiz687.
55. Peccia J, Zulli A, Brackney DE, Grubaugh ND, Kaplan EH, Casanovas-Massana A, Ko AI, Malik AA, Wang D, Wang M, Warren JL, **Weinberger DM**, Arnold W, Omer SB. Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics. *Nature Biotechnology*. 2020;38(10):1164-7. Epub 2020/09/20. doi: 10.1038/s41587-020-0684-z.
56. Phillips MT, Warren JL, Givon-Lavi N, Tothpal A, Regev-Yochay G, Dagan R, **Weinberger DM**. Evaluating post-vaccine expansion patterns of pneumococcal serotypes. *Vaccine*. 2020;38(49):7756-63. Epub 2020/11/10. doi: 10.1016/j.vaccine.2020.10.045.
57. Pokutnaya D, Molaei G, **Weinberger DM**, Vossbrinck CR, Diaz AJ. Prevalence of Infection and Co-Infection and Presence of Rickettsial Endosymbionts in Ixodes Scapularis (Acari: Ixodidae) in Connecticut, USA. *Journal of Parasitology*. 2020;106(1):30-7. Epub 2020/01/24.
58. Shioda K, de Oliveira LH, Sanwogou J, Rey-Benito G, Nuñez Azzad D, Castillo RE, Gamarra Ramírez ML, Von Horoch MR, **Weinberger DM**, Pitzer VE. Identifying signatures of the impact of rotavirus vaccines on hospitalizations using sentinel surveillance data from Latin American countries. *Vaccine*. 2020;38(2):323-9. Epub 2019/11/02. doi: 10.1016/j.vaccine.2019.10.010.
59. Shioda K, Toscano CM, Valenzuela MT, Huarcaya WV, Warren JL, **Weinberger DM**, de Oliveira LH. Impact of pneumococcal conjugate vaccine uptake on childhood pneumonia mortality across income levels in Brazil, Colombia, and Peru. *Gates Open Research*. 2020;4:136. Epub 2021/01/16. doi: 10.12688/gatesopenres.13187.1.
60. Warren JL, **Weinberger DM**. Estimating Serotype-specific Efficacy of Pneumococcal Conjugate Vaccines Using Hierarchical Models. *Epidemiology*. 2020;31(2):259-62. Epub 2020/01/09. doi: 10.1097/ede.0000000000001135.
61. **Weinberger DM**, Chen J, Cohen T, Crawford FW, Mostashari F, Olson D, Pitzer VE, Reich NG, Russi M, Simonsen L, Watkins A, Viboud C. Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020. *JAMA Internal Medicine*. 2020;180(10):1336-44. Epub 2020/07/02. doi: 10.1001/jamainternmed.2020.3391.
62. **Weinberger DM**, Warren JL. Estimating the power to detect a change caused by a vaccine from time series data. *Gates Open Research*. 2020;4:27. Epub 2020/10/31. doi: 10.12688/gatesopenres.13116.2.
63. Woolf SH, Chapman DA, Sabo RT, **Weinberger DM**, Hill L. Excess Deaths From COVID-19 and Other Causes, March-April 2020. *JAMA*. 2020;324(5):510-3. Epub 2020/07/02. doi: 10.1001/jama.2020.11787.
64. Woolf SH, Chapman DA, Sabo RT, **Weinberger DM**, Hill L, Taylor DDH. Excess Deaths From COVID-19 and Other Causes, March-July 2020. *JAMA*. 2020;324(15):1562-4. Epub 2020/10/13. doi: 10.1001/jama.2020.19545.
65. Andersen MA, Niemann CU, Rostgaard K, Dalby T, Sørrig R, **Weinberger DM**, Hjalgrim H, Harboe ZB. Differences and Temporal Changes in Risk of Invasive Pneumococcal Disease in Adults with Hematological Malignancies: Results from a Nationwide 16-Year Cohort Study. *Clinical Infectious Diseases*. 2021;72(3):463-71. Epub 2020/05/29. doi: 10.1093/cid/ciaa090.
66. Artin B, Pitzer VE, **Weinberger DM**. Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996-2013. *Scientific Reports*. 2021;11(1):10684. Epub 2021/05/23. doi: 10.1038/s41598-021-90107-8.
67. Brackney MM, **Weinberger DM**, Higgins K, Meek J, Niccolai LM. Trends in Precancerous Cervical Lesions by Area-Based Measures of Poverty, Race, and Ethnicity, Connecticut, 2008-2018. *Public Health Reports*. 2021:333549211056300. Epub 2021/11/03. doi: 10.1177/00333549211056300.
68. Cassell K, Kjelsø C, **Weinberger DM**, Uldum SA. Evidence for multiple cases of recurrent Legionella infection: a Danish national surveillance study. *Thorax*. 2021. Epub 2021/01/29. doi: 10.1136/thoraxjnl-2020-216344.
69. Danino D, Ben-Shimol S, Van Der Beek BA, Givon-Lavi N, Avni YS, Greenberg D, **Weinberger DM**, Dagan R. Decline in Pneumococcal Disease in Young Children during the COVID-19 Pandemic in Israel Associated with Suppression of seasonal Respiratory Viruses, despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. *Clinical Infectious Diseases*. 2021. Epub 2021/12/15. doi: 10.1093/cid/ciab1014.
70. de Oliveira LH, Shioda K, Valenzuela MT, Janusz CB, Rearte A, Sbarra AN, Warren JL, Toscano CM, **Weinberger DM**. Declines in Pneumonia Mortality Following the Introduction of Pneumococcal Conjugate Vaccines in Latin American and Caribbean Countries. *Clinical Infectious Diseases*. 2021;73(2):306-13. Epub 2020/05/26. doi: 10.1093/cid/ciaa614.
71. Ehrlich HY, Bei AK, **Weinberger DM**, Warren JL, Parikh S. Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. *PNAS*. 2021;118(29). Epub 2021/07/16. doi: 10.1073/pnas.2100685118.
72. Ehrlich HY, Harizaj A, Campbell L, Colt M, Yuan K, Rabatsky-Ehr T, **Weinberger DM**, Leung V, Niccolai LM, Parikh S. SARS-CoV-2 in Nursing Homes after 3 Months of Serial, Facilitywide Point Prevalence Testing, Connecticut, USA. *Emerging Infectious Diseases.*2021;27(5):1288-95. Epub 2021/04/27. doi: 10.3201/eid2705.204936.
73. Kleynhans J, Tempia S, Shioda K, von Gottberg A, **Weinberger DM**, Cohen C. Estimated impact of the pneumococcal conjugate vaccine on pneumonia mortality in South Africa, 1999 through 2016: An ecological modelling study. *PLoS Medicine.* 2021;18(2):e1003537. Epub 2021/02/17. doi: 10.1371/journal.pmed.1003537.
74. Knight JR, Dunne EM, Mulholland EK, Saha S, Satzke C, Tothpal A, **Weinberger DM**. Determining the serotype composition of mixed samples of pneumococcus using whole-genome sequencing. *Microbial Genomics*. 2021;7(1). Epub 2020/12/24. doi: 10.1099/mgen.0.000494.
75. Lajous M, Huerta-Gutiérrez R, Kennedy J, Olson DR, **Weinberger DM**. Excess Deaths in Mexico City and New York City During the COVID-19 Pandemic, March to August 2020. *American Journal of Public Health*. 2021;111(10):1847-50. Epub 2021/09/10. doi: 10.2105/ajph.2021.306430.
76. Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, **Weinberger DM**. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. *JAMA Internal Medicine*. 2021. Epub 2021/12/01. doi: 10.1001/jamainternmed.2021.7382.
77. Pitzer VE, Chitwood M, Havumaki J, Menzies NA, Perniciaro S, Warren JL, **Weinberger DM**, Cohen T. The Impact of Changes in Diagnostic Testing Practices on Estimates of COVID-19 Transmission in the United States. *American Journal of Epidemiology*. 2021;190(9):1908-17. Epub 2021/04/09. doi: 10.1093/aje/kwab089.
78. Prunas O, **Weinberger DM**, Medini D, Tizzoni M, Argante L. Evaluating the Impact of Meningococcal Vaccines With Synthetic Controls. *American Journal of Epidemiology*. 2021. Epub 2021/11/10. doi: 10.1093/aje/kwab266.
79. Reyburn R, Tuivaga E, Nguyen CD, Ratu FT, Nand D, Kado J, Tikoduadua L, Jenkins K, de Campo M, Kama M, Devi R, Rafai E, **Weinberger DM**, Mulholland EK, Russell FM. Effect of ten-valent pneumococcal conjugate vaccine introduction on pneumonia hospital admissions in Fiji: a time-series analysis. *Lancet Global Health*. 2021;9(1):e91-e8. Epub 2020/11/24. doi: 10.1016/s2214-109x(20)30421-6.
80. Sharma R, Kuohn LR, **Weinberger DM**, Warren JL, Sansing LH, Jasne A, Falcone G, Dhand A, Sheth KN. Excess Cerebrovascular Mortality in the United States During the COVID-19 Pandemic. *Stroke*. 2021;52(2):563-72. Epub 2021/01/13. doi: 10.1161/strokeaha.120.031975.
81. Shioda K, Cai J, Warren JL, **Weinberger DM**. Incorporating Information on Control Diseases Across Space and Time to Improve Estimation of the Population-level Impact of Vaccines. *Epidemiology*. 2021;32(3):360-7. Epub 2021/03/31. doi: 10.1097/ede.0000000000001341.
82. Watkins AE, Fenichel EP, **Weinberger DM**, Vogels CBF, Brackney DE, Casanovas-Massana A, Campbell M, Fournier J, Bermejo S, Datta R, Dela Cruz CS, Farhadian SF, Iwasaki A, Ko AI, Grubaugh ND, Wyllie AL. Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples. *Emerging Infectious Diseases.*2021;27(4):1184-7. Epub 2021/03/24. doi: 10.3201/eid2704.204200.
83. Wyllie AL, Warren JL, Regev-Yochay G, Givon-Lavi N, Dagan R, **Weinberger DM**. Serotype Patterns of Pneumococcal Disease in Adults Are Correlated With Carriage Patterns in Older Children. *Clinical Infectious Diseases*. 2021;72(11):e768-e75. Epub 2020/09/30. doi: 10.1093/cid/ciaa1480.
84. Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, **Weinberger DM**. Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US. *JAMA Network Open*. 2021;4(12):e2141779. Epub 2021/12/17. doi: 10.1001/jamanetworkopen.2021.41779.
85. Zheng Z, Pitzer VE, Warren JL, **Weinberger DM**. Community factors associated with local epidemic timing of respiratory syncytial virus: A spatiotemporal modeling study. *Science Advances* 2021;7(26). Epub 2021/06/25. doi: 10.1126/sciadv.abd6421.
86. Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, **Weinberger DM\***, Pitzer VE\*. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. *Science*. 2022:eabl4292. Epub 2022/01/28. doi: 10.1126/science.abl4292. (\*contributed equally)
87. Zheng Z, Warren JL, Artin I, Pitzer VE, **Weinberger DM**. Relative timing of RSV epidemics in summer 2021 across the US was similar to a typical RSV season*. Influenza and Other Respiratory Viruses.* *In press.*
88. Chaguza C, Coppi A, Earnest R, Ferguson D, Kerantzas N, Warner F, Young HP, Breban MI, Billig K, Koch RT, Pham K, Kalinich CC, Ott IM, Fauver JR, Hahn AM, Tikhonova IR, Castaldi C, De Kumar B, Pettker CM, Warren JL, **Weinberger DM**, Landry ML, Peaper DR, Schulz W, Vogels CBF, Grubaugh ND. Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons. Med (N Y). 2022 Apr 6. doi: 10.1016/j.medj.2022.03.010. Epub ahead of print. PMID: 35399324; PMCID: PMC8983481.
89. Prunas O, **Weinberger DM**, Pitzer VE, Gazit S, Palaton T Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents. *Clinical Infectious Diseases, In press.*
90. Chitwood MH, Russi M, Gunasekera K, Havumaki J, Klaassen F, Pitzer VE, Solomon JA, Swartwood NA, Warren JL, **Weinberger DM**, Cohen T, Menzies NA. Reconstructing the course of the COVID-19 epidemic over 2020 for US states and counties: results of a Bayesian evidence synthesis model *PLOS Computational Biology. In press.*
91. Ryman J, Weaver J, Hu H, **Weinberger DM**, Yee KL, Sachs J. Predicting Vaccine Effectiveness Against Invasive Pneumococcal Disease in Children using Immunogenicity Data. *NPJ Vaccines,* In press.
92. Cassell K, Zipfel C, **Weinberger DM**, Bansal S. Trends in non-COVID-19 hospitalizations prior to and during the COVID-19 pandemic period, United States, 2017 – 2021. *Nature Communications.* 2022*. In press.*

*Reviews and commentaries*

1. **Weinberger DM**, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. *Lancet*. 2011;378(9807):1962-73. Epub 2011/04/16. doi: 10.1016/s0140-6736(10)62225-8.
2. **Weinberger DM**, Shapiro ED. Pneumococcal conjugate vaccines for adults: reasons for optimism and for caution. *Human Vaccines and Immunotherapeutics*. 2014;10(5):1334-6. Epub 2014/04/26. doi: 10.4161/hv.28962.
3. Bruhn CA, Schuck-Paim C, Kürüm E, Taylor RJ, Simonsen L, **Weinberger DM**. Improving Assessments of Population-level Vaccine Impact. *Epidemiology*. 2017;28(2):233-6. Epub 2016/12/07. doi: 10.1097/ede.0000000000000598.
4. Metcalf CJE, Walter KS, Wesolowski A, Buckee CO, Shevliakova E, Tatem AJ, Boos WR, **Weinberger DM**, Pitzer VE. Identifying climate drivers of infectious disease dynamics: recent advances and challenges ahead. *Proceedings of the Royal Society: Biological Sciences*. 2017;284(1860). Epub 2017/08/18. doi: 10.1098/rspb.2017.0901.
5. **Weinberger DM**. Filling evidence gaps on the impact of pneumococcal vaccines. *Lancet Infectious Diseases*. 2017;17(9):888-9. Epub 2017/06/12. doi: 10.1016/s1473-3099(17)30328-6.
6. **Weinberger DM**, Harboe ZB, Shapiro ED. Developing Better Pneumococcal Vaccines for Adults. *JAMA Internal Medicine*. 2017;177(3):303-4. Epub 2017/01/19. doi: 10.1001/jamainternmed.2016.8289.
7. Chan J, Nguyen CD, Dunne EM, Kim Mulholland E, Mungun T, Pomat WS, Rafai E, Satzke C, **Weinberger DM**, Russell FM. Using pneumococcal carriage studies to monitor vaccine impact in low- and middle-income countries. *Vaccine*. 2019;37(43):6299-309. Epub 2019/09/11. doi: 10.1016/j.vaccine.2019.08.073.
8. **Weinberger DM**, Shapiro ED. Prevention of Pneumococcal Infections in Adults Using Conjugate Vaccines: No Easy Answers. *Clinical Infectious Diseases*. 2019;69(1):50-1. Epub 2018/10/13. doi: 10.1093/cid/ciy873.
9. Arguedas A, Trzciński K, O'Brien KL, Ferreira DM, Wyllie AL, Weinberger D, Danon L, Pelton SI, Azzari C, Hammitt LL, Sá-Leão R, Brandileone MC, Saha S, Suaya J, Isturiz R, Jodar L, Gessner BD. Upper respiratory tract colonization with Streptococcus pneumoniae in adults. *Expert Reviews Vaccines*. 2020;19(4):353-66. Epub 20200417. doi: 10.1080/14760584.2020.1750378.
10. Shioda K, **Weinberger DM**, Mori M. Navigating Through Health Care Data Disrupted by the COVID-19 Pandemic. *JAMA Internal Medicine*. 2020;180(12):1569-70. Epub 2020/10/13. doi: 10.1001/jamainternmed.2020.5542.
11. **Weinberger DM**, Shapiro ED. Pneumococcal Vaccines for Adults: What's Next? *Clinical Infectious Diseases*. 2020;70(12):2493-5. Epub 2019/08/14. doi: 10.1093/cid/ciz743.
12. Dagan R, Danino D, **Weinberger DM**. The Pneumococcus-Respiratory Virus Connection-Unexpected Lessons From the COVID-19 Pandemic. JAMA Netw Open. 2022 Jun 1;5(6):e2218966. doi: 10.1001/jamanetworkopen.2022.18966. PMID: 35763301.
13. Mazur N, [Many authors], Bont L, Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape, *The Lancet Infectious Diseases,* 2022*. In press*

*Journal Correspondence*

1. **DM Weinberger**, Bruhn CAW\*, Shapiro ED. Vaccine against pneumococcal pneumonia in adults. *New England Journal of Medicine*. 2015 Jul 2;373(1):92.

*Preprints awaiting peer review*

1. Althouse BM, **Weinberger DM**, Scarpino SV, Pitzer VE, Ayers JW, Wenger E, Chun-Hai Fung I, Dredze M, Hu H. Google searches accurately forecast RSV hospitalizations. *bioRxiv*. <https://doi.org/10.1101/607119>
2. York A, Mbodj S, Yolda-Carr D, Hislop M, **Weinberger DM**, Wyllie AL. Magnetic Bead-Based Separation (MBS) of Pneumococcal Serotypes. *bioRxiv* 2021.06.06.447277; doi: <https://doi.org/10.1101/2021.06.06.447277>

*Software*

InterventionEvaluatR: An R package to evaluate the effects of vaccines using administrative data. R package version 0.1. **Daniel Weinberger** and Iris Artin (2018)

ExcessILI: A package and RShiny app to examine excess ILI from syndromic surveillance data. R package version 0.1. **Daniel Weinberger** and Marcus Russi (2020).

*Popular press*

I was the academic leader of the Yale-*Washington Post* “COVID Counting Consortium”, which was active from April-September 2020. This group included faculty and students from Yale, along with colleagues at the NIH, Harvard, and Aledade, working closely with the editors, writers, and data reporters from the *Washington* *Post*’s investigative journalism team. I contributed to a series of stories in the *Washington Post* on the death toll of COVID-19 in the United states and globally, and my group’s research was featured in several lead front-page articles on the topic.